

YOU. Where vitality begins.

As a health professional, you help your patients seek and achieve lasting quality of life. It is you who opens the door to bone health assessment, diagnosis, and treatment or prevention. Achilles is here to help. It makes proven fracture risk assessment widely accessible. And that's vital for you and your patients.

Achilles offers accurate fracture risk assessment that is comfortable for patients and convenient for operators. All to help you provide better care to more patients.







Osteoporotic fracture risk assessment as discriminating as DXA at the hip and spine.

The osteoporotic fracture risk assessment provided by Achilles closely matches prevalence as defined by central DXA (see chart below).¹ Yet it's fast and affordable.

Its high negative predictive value - 97 percent for 50- to 59-year-old Caucasian women - makes Achilles especially useful for discriminating between those not at risk for fracture and those in need of further evaluation by central DXA.⁴

Additionally, Achilles has proven long-term precision, making it useful for monitoring bone changes.^{5,6,7} It's the only QUS device cleared for monitoring by the Food and Drug Administration.

sation allows measurement over a wide range of bone density Comparison of Achilles and competitive ultrasonometers Bi-directional measurement to DXA for osteoporosis testing ensures a consistent reading Percentage of 60-year-old women that tested positive for osteoporosis Measurement site temperature is controlled for more accuracy Estimated osteoporosis prevalence (%) (60-year-old women) Among these ultrasonometers, Achilles 50 most closely matches DXA findings based on the percentage of 60-year-old Results expressed as Stiffness women it determines to have osteopo-40 Index — a composite of Speed rosis, as defined by a DXA T-score <-2.5 at the femoral neck of Sound (SOS) and Broadband 30 Ultrasound Attenuation (BUA) — 50% compensate for the effect of 20 heel width and temperature 24% Real-time image provides visual 4% confirmation of proper heel Sahara** QUI Omnisense* radius SOS Central DXA (femoral IGEA** DBM placement (Achilles Insight only) Better care can be anywhere with Achilles Achilles provides fast, affordable, easily portable care, helping you reach more patients with the accurate assessment and follow-up care they need. Certainty.

Clinical confidence is


based on many features:

Dynamic signal strength compen-





A large, easy-to-read color display tilts back and forth.



Convenience.


Efficient, customizable workflow.

Your staff will appreciate the simplicity of Achilles. It's easy for technicians to learn and to use, and it requires no special rooms, no formal training, and no licensing. Results are concise and easy to interpret.

Along with rugged durability, Achilles boasts plenty of technical features. A large, easy-to-read color display tilts back and forth. Reports print out in full color and full size. The on-board memory stores up to 2,000 patient records. And customizable measurement workflows allow you to select which data to collect and report:

- Prevalence data
- Clinical risk factors
- Patient identification data





Vitality for your patients means vitality for your business

When more patients know their risk of fracture, there are benefits for you and your business, too. The ongoing monitoring capabilities of Achilles, as well as the fast, comfortable exam, all can contribute to increased patient loyalty.

Do you want to raise awareness of osteoporosis among the general public? Assess risk to make the most efficient use of your central DXA system? Or provide direct osteoporosis management? Whatever your goal, Achilles can help.

Contact your
GE Healthcare
representative for
more information
on Achilles

Leading hospitals, clinics, and physicians trust Achilles to help provide better care for their patients.

- Krieg M-A, Barkmann R, Gonnelli S, et al. Quantitative Ultrasound in the Management of Osteoporosis: The 2007 ISCD Official Positions. J Clin Densitom: Assessment of Skeletal Health. 2008;11(1):163-187.
- 2. Hans D, Dargent-Molina P, Schott AM, et al. Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. *Lancet*. 1996;348(9026):511-514.
- Glüer Claus C, Eastell R, Reid DM, et al. Association of Five Quantitative Ultrasound Devices and Bone Densitometry With Osteoporotic Vertebral Fractures in a Population-Based Sample: The OPUS Study. J Bone Miner Res. 2004;19(5):782-793.
- 4. Simon D, Boring III JR. Chap. 6: Sensitivity, Specificity, and Predictive Value. In: HK Walker, WD Hall, JW Hurst, ed. *Clinical Methods: The History, Physical, and Laboratory Examinations*, 3rd edition. Boston: Butterworths; 1990.
- 5. Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Rossi S, Gennari C. Ultrasound parameters in osteoporotic patients treated with salmon calcitonin: A longitudinal study. *Osteoporos Int.* 1996:6(4):303-307.
- Giorgino R, Paparella AP, Lorusso D, Mancuso S. Effects of oral alendronate treatment and discontinuance on ultrasound measurements of the heel in postmenopausal osteoporosis. North American Menopausal Society, September 1996.
- 7. Gonnelli S, Cepollaro C, Montagnani A, et al. Heel ultrasonography in monitoring alendronate therapy: a four-year longitudinal study. *Osteoporos Int.* 2002;13(5):415-421.

About GE Healthcare:

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

To receive Lunar News online, please register for **SmartMail**. Go to **www.gehealthcare.com/company/smartmail.html** and register to automatically receive the newsletter.

©2011 General Electric Company - All rights reserved.

GE and GE Monogram are trademarks of General Electric Company. *Achilles is a trademark of General Electric Company. **All third-party trademarks are the property of their respective owner.

General Electric Company reserves the right to make changes in specifications and features shown herein, or discontinue the product described at any time without notice or obligation. Contact your GE representative for the most current information.

GE Medical Systems Ultrasound & Primary Care Diagnostics, LLC, a General Electric company, doing business as GE Healthcare

Lunar Product Division:

GE Healthcare Lunar Global Headquarters PO Box 7550 Madison, WI 53707-7550 T: +1-800-535-7339 F: +1-608-223-2482

Europe, Middle-East & Africa

GE Healthcare Lunar Kouterveldstraat 20 B-1831 Diegem, Belgium T: +32-2-7197217 F: +32-2-7197359 info.lunar@ge.com

Asia & Pacific

GE Healthcare Lunar3/F GE China Technology Park
No. 1 Hua Tuo Road
Shanghai 201203, China
T: +86-21-38777888 (Ext. 60128 or 60480)
F: +86-21-38777451

